Abstract
#Glioblastomamultiforme (GBM) is the most common and lethal primary
brain tumor with an inevitable fatal outcome. However, the
complex network of #dysregulatedpathways in #glioblastoma development and
progression remains to be poorly understood. Consequently, novel
approaches for the treatment of glioblastoma are seriously needed and
the search for new target molecules for #pharmacologicinterventionis in the focus of research. Since it is known that CK1 isoforms are
involved in Wnt/β-catenin and sonic hedgehog signal transduction
pathways, which are often dysregulated in glioblastoma cells, inhibition
of CK1 isoforms might hold therapeutic potential. Therefore, two
previously characterized CK1 isoform-selective
#difluoro-dioxolo-benzoimidazole derivatives were investigated on their
effects on the viability
of glioblastoma cell lines. Compound 2 showed major effects on the
tested cells with EC50 values below 100 nM in most of the
analyzed
#glioblastomacell lines. Cell cycle analyses underlined the observation
that compound 2 is most effective since treatment with compound 2
induced cell death in up to 57% of the analyzed cells. In conclusion,
our data point to a high therapeutic potential of CK1 isoform-selective
inhibitors for the treatment of glioblastoma.
#Inhibition of CK1 affects Viability and Survival of #GlioblastomaCells by Joachim Bischof in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.